Academia

  • Email
  • Help

Information for you

On this page, you will find information on the European Medicines Agency’s (EMA) activities that are most relevant to academia, including news and events.

Learn more about the Agency's resources to support medicine development:

Human regulatory: Research and development
Veterinary regulatory: Research and development

Learn more about how EMA interacts with academia.

Featured information

News for academia

Events of interest

  • 20/03/2018

    PDCO

    Multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation

    This workshop, organised by the European Medicines Agency (EMA) and the European Commission, follows the publication of the Commission’s ten-year report on implementation of the Paediatric Regulation and the state of paediatric medicines in the European Union. The aim is to discuss potential improvements of the implementation of the Regulation. It will explore opportunities regarding paediatric needs, timely completion of paediatric investigation plans (PIP), and processes and expectations for handling PIP applications. This workshop is a crucial step for the development of a concrete action plan to address challenges identified with medicine development for children in Europe. Invited stakeholders include patients, academia, healthcare professionals and industry. The deadline for expressions of interest is 14 February. EMA will select industry stakeholders via registered associations. The Agency will contact all selected participants on 1 March. ... Read more

  • 05/09/2018 - 06/09/2018

    PDCO

    Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

    The third multi-stakeholder Paediatric Strategy Forum, jointly organised by EMA and ACCELERATE will focus on checkpoint inhibitors used in combination therapy, in children and adolescents. This Forum will reviewed the immunological environment of paediatric malignancies, checkpoint inhibitors in early phase clinical studies in paediatrics, strategies combining checkpoint inhibitors with other products and alternative immunotherapy strategies. Participation is restricted and on invitation only. Interested parties, including patients and parent-representatives, academia, clinicians and industry, should express their interest using the forms linked to this page. ... Read more

  • 19/04/2018

    CVMP

    European Medicines Agency veterinary medicines innovation day

    The purpose of the European Medicines Agency (EMA) veterinary medicines innovation day is to raise awareness and promote the support and measures that the Agency has to offer in the area of veterinary medicines innovation. The event is aimed at industry, including micro, small and medium-sized enterprises (SMEs) and veterinary consultants. The information provided will also be beneficial to academia, veterinary healthcare professionals and national competent authorities. ... Read more

  • 04/05/2018

    EMA

    Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) Joint Big Data Task Force meeting: Identifying solutions for big data challenges

    The aim of this workshop is to inform thinking on big data and related challenges as the HMA/EMA Joint Big Data Task Force is planning to make recommendations in this field in November 2018. In 2017, the task force undertook detailed landscaping of the entire big data field (genomics through to m-health) as viewed through the lens of the regulator. It also performed online surveys of both national regulatory agencies and the pharmaceutical industry on perspectives, expertise and challenges. This work helped develop an understanding of the challenges and the current state of expertise in the regulatory network. The taskforce now aims to move onto considering solutions. The task force was established in March 2017 to identify the emerging challenges created by the increasing availability of data and related opportunities for supporting regulatory decision-making. ... Read more

  • 28/02/2018

    MB

    Extraordinary Management Board meeting: 28 February 2018

    This extraordinary Management Board meeting is to consider the building approval process for EMA’s premises in Amsterdam. The Management Board is an integral governance body of the Agency. It has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director and the monitoring of the Agency’s performance. ... Read more

  • See all Events of interest

Information for:

Find information for...

Innovation_in_medicines

advanced_theraphy_medicinal_products

Orphan_designation

Scientific_advice_protocol_assistance